Table 2

Factors associated with long-term progression-free survival in patients treated with niraparib using the alternative definition of categorical progression-free survival

Baseline characteristicOR (95% CI)Overall p value
ECOG performance status vs 1
01.54 (0.94 to 2.52)0.086
FIGO stage at diagnosis vs stage IV
III1.79 (1.11 to 2.88)0.018
Primary tumor location vs ovarian
Primary peritoneal0.49 (0.18 to 1.30)0.090
Fallopian0.53 (0.26 to 1.07)
BRCA/homologous recombination-deficiency status vs BRCA wild-type/homologous recombination-proficient/homologous recombination not determined
BRCA1 mutated/homologous recombination-deficient3.81 (2.20 to 6.62)
BRCA2 mutated/homologous recombination-deficient12.55 (5.62 to 28.06)<0.0001
BRCA wild-type/BRCA not determined/homologous recombination-deficient2.95 (1.63 to 5.35)
Baseline non-target lesion number vs ≥2 lesions
05.52 (2.42 to 12.56)<0.0001
12.43 (0.93 to 6.37)
  • p value estimated using the type III test for analysis of effects.

  • This analysis was conducted as a sensitivity analysis for the definition of categorical long-term progression-free survival.

  • ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics.